English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe survey results illustrate the care barriers that rural and frontier communities face throughout the Mountain West. This groundbreaking work helps Huntsman Cancer Institute address these disparities more effectively.
Tag: Cancer Clinical Trials
NCCN Oncology Research Program Celebrates 25 Years of Advancing Cancer Science
The National Comprehensive Cancer Network (NCCN)’s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
UC San Diego Health First in Region to Provide Novel Therapy for Melanoma
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
Five Questions Parents Should Ask Their Child’s Oncologist About Participating in a Clinical Trial
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
UChicago Medicine-led team selected for the 2022 Michael & Lori Milken Family Foundation-PCF Challenge Award to develop novel immunotherapy approaches in advanced prostate cancer
The Prostate Cancer Foundation (PCF) has awarded a $1 million grant to a renowned specialist at the University of Chicago Medicine Comprehensive Cancer Center.
Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer
A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.
KU Cancer Center uses art to reach underserved communities
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.
Triple-drug therapy for post-transplant management of multiple myeloma
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
Understanding How the Perception of Risks and Benefits Influence Cancer Clinical Trial Withdrawal Outcomes
While people with cancer have options to participate in cancer clinical trials (CCTs), it can be challenging when they encounter difficulties enrolling and remaining in the trial. Trial withdrawal, although every participant’s right, can thwart study goals and hamper advancing novel treatments.
Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients
CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.
NCI renews prestigious ‘comprehensive’ designation for cancer center
The National Cancer Institute renewed the “comprehensive” designation of the UC Davis Comprehensive Cancer Center in recognition of its breadth and depth in cancer research, clinical care, cancer control and population sciences.
Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
University of Chicago Medicine Comprehensive Cancer Center Researcher Receives National Cancer Clinical Investigator Team Leadership Award
Daniel Catenacci, MD, a physician-scientist and associate professor of medicine at UChicago Medicine, has received the National Cancer Institute (NCI) 2021 Cancer Clinical Investigator Team Leadership Award (CCITLA).
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27
Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 63rd Annual Meeting, which will return to an in-person conference at McCormick Place West in Chicago, October 24-27, 2021. Media resources and registration are available at www.astro.org/astro2021press, and general registration is available at www.astro.org/annualmeeting.
UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell Therapy
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
Mount Sinai to Lead a Team Awarded $6 Million to Decrease Disparities in Cancer Clinical Trials
Mount Sinai researchers have received a grant award to lead a collaborative team of New York institutions in an initiative that addresses disparities in the participation of Black, indigenous, and people of color (BIPOC) in cancer clinical trials.
Henry Ford Health System is First in the U.S. to Perform Procedure Using CG-100 Device for Colorectal Cancer Patients
Henry Ford Health System is the first in the country to perform a procedure using the CG-100 intraluminal device, which is temporarily inserted into the gastrointestinal tract and designed to reduce diverting stoma rates, and the need for an ostomy bag, in patients undergoing gastrointestinal resection procedures due to colorectal cancer treatment.
Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.
Variations in side effect reporting makes drug safety unclear
University of Colorado Cancer Center study of early-phase clinical trials finds variations in reporting of drug side effects, potentially obscuring safety.
Grounded in Science
Doctors face a difficult decision when they must choose a drug combination that will benefit the person sitting before them in an exam room. Statistics can’t show how any one person will respond to a reatment.works in people. Dr. Sarah Adams is using a $1.2M to find better ways to predict which women will benefit from her drug combination, now in clinical trials.
Select few cancer patients enroll in potentially life-extending clinical trials
Patient enrollment in clinical trials as the first course of treatment after cancer diagnosis is low, despite the fact that enrollment may increase life expectancy, according to researchers at Penn State.
The University of Chicago Medicine to Honor Breast Cancer Specialist Laura Esserman
Breast cancer specialist Laura Esserman, MD, MBA, is being honored for excellence in the field of cancer research with an award from the University of Chicago Medicine Comprehensive Cancer Center.